BAYRY Stock Recent News

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the launch of its Imaging Core Lab Services under the brand name Centafore. With over 25 years of experience supporting more than 200 clinical trials at Bayer and its arm's length companies globally, Centafore is now positioned as a distinct Imaging solution provider, offering tailored services for external customers to support their clinical trials and Software as a Medical Device (SaMD) development across diverse therapeutic areas and dev.

The phase I study evaluates BAYRY's investigational GIRK4 inhibitor, BAY 3670549, for the treatment of patients with atrial fibrillation.

WHIPPANY, N.J.--(BUSINESS WIRE)--The latest data from studies across Bayer's oncology and women's health portfolios will be presented at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago from May 30–June 3. These data underscore Bayer's commitment to advancing treatments across different stages of cancer and driving the development of healthcare treatments, including for prostate and lung cancer. This year's ASCO presence also underscores Bay.

May is Women's Health Month – Dr. Yesmean Wahdan Shares Important and Timely Tips to Help Women Prioritize Their Health at Every Life Stage May is Women's Health Month – Dr. Yesmean Wahdan Shares Important and Timely Tips to Help Women Prioritize Their Health at Every Life Stage

Bayer A.G.'s stock is very cheap and near multi-year lows, but ongoing declines and uncertain turnaround make it risky for conservative investors. Pharmaceuticals and consumer health divisions are showing rising sales, while crop science is under pressure and facing regulatory risks, especially with glyphosate. Recent earnings disappointed, with declining profitability and net losses, but operational cash flow has improved, and sales remain stable.

Bayer is seeking to resolve lawsuits related to its Roundup weedkiller, while exploring a bankruptcy for its Monsanto unit if the settlement plan fails, the Wall Street Journal reported on Thursday, citing people familiar with the matter.

The agricultural giant is preparing to place its U.S. subsidiary Monsanto in bankruptcy if a settlement with tort plaintiffs fails

Bayer Pharmaceuticals' chief operating officer said the head of the top U.S. drug regulator recently reassured industry executives that the Food and Drug Administration would meet its targets for reviews despite recent job cuts and a restructuring.

Bayer AG BAYRY reported on Tuesday that the first quarter of 2025 net profit was 1.3 billion euros (around $1.45 billion), down from 2 billion euros a year ago.

Bayer A.G. (OTCPK:BAYZF) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Bill Anderson - Chairman & CEO Wolfgang Nickl - CFO Rodrigo Santos - President, Crop Science Division Stefan Oelrich - President, Pharmaceuticals Division Conference Call Participants Richard Vosser - JPMorgan Sachin Jain - Bank of America Merrill Lynch James Quigley - Goldman Sachs Jo Walton - UBS Christian Feitz - Kepler Cheuvreux Vincent Andrews - Morgan Stanley Laurent Favre - BNP Paribas Operator Good afternoon and good morning, everybody, and welcome to our conference call to discuss the first quarter results for 2025. To kick things off, Bill will share insights on our overall business performance and the progress we've made on our strategic priorities thus far.